Loes Vecht1, Susanna M Zuurbier1, Joost C M Meijers2,3, Jonathan M Coutinho4. 1. Department of Neurology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. 2. Department of Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3. Department of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands. 4. Department of Neurology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. j.coutinho@amc.uva.nl.
Abstract
BACKGROUND: Elevated factor VIII (FVIII) is a risk factor for leg-vein thrombosis and pulmonary embolism. We assessed whether elevated FVIII is also a risk factor for cerebral venous thrombosis (CVT). METHODS: We performed a matched case-control study. We assessed patients with CVT, as cases, admitted between July 2006 and December 2016. The controls were healthy hospital-staff employees matched for age (within 5 years) and sex. FVIII activity was measured at least 3 months after CVT diagnosis. Elevated FVIII was defined as activity > 150 IU/dl. We used logistic regression analysis, adjusting for age and sex. RESULTS: We included 116 cases and 116 controls (85% women for both groups). Mean age was 40 (SD 11) and 41 (SD 11) years for cases and controls, respectively. Median time between CVT diagnosis and blood collection was 18 months (IQR 7-39 months). Cases more often had elevated FVIII as compared to controls (83.6 vs 28.4%, p < 0.001). After adjustment, elevated FVIII was associated with a 15-fold increased risk of CVT (OR 15.3, 95% CI 7.8-30.1). Stratification by sex showed a stronger association in men (OR 22.8, 95% CI 2.8-184.3) than in women (OR 14.7, 95% CI 7.2-30.2). CONCLUSION: Elevated FVIII occurs frequently in patients with CVT and is a strong risk factor for this condition.
BACKGROUND: Elevated factor VIII (FVIII) is a risk factor for leg-vein thrombosis and pulmonary embolism. We assessed whether elevated FVIII is also a risk factor for cerebral venous thrombosis (CVT). METHODS: We performed a matched case-control study. We assessed patients with CVT, as cases, admitted between July 2006 and December 2016. The controls were healthy hospital-staff employees matched for age (within 5 years) and sex. FVIII activity was measured at least 3 months after CVT diagnosis. Elevated FVIII was defined as activity > 150 IU/dl. We used logistic regression analysis, adjusting for age and sex. RESULTS: We included 116 cases and 116 controls (85% women for both groups). Mean age was 40 (SD 11) and 41 (SD 11) years for cases and controls, respectively. Median time between CVT diagnosis and blood collection was 18 months (IQR 7-39 months). Cases more often had elevated FVIII as compared to controls (83.6 vs 28.4%, p < 0.001). After adjustment, elevated FVIII was associated with a 15-fold increased risk of CVT (OR 15.3, 95% CI 7.8-30.1). Stratification by sex showed a stronger association in men (OR 22.8, 95% CI 2.8-184.3) than in women (OR 14.7, 95% CI 7.2-30.2). CONCLUSION: Elevated FVIII occurs frequently in patients with CVT and is a strong risk factor for this condition.
Entities:
Keywords:
Case–control study; Cerebral venous thrombosis; Coagulation factor VIII
Authors: Jonathan M Coutinho; Susanna M Zuurbier; Aafke E Gaartman; Arienne A Dikstaal; Jan Stam; Saskia Middeldorp; Suzanne C Cannegieter Journal: Stroke Date: 2015-08-13 Impact factor: 7.914
Authors: Suzanne M Silvis; Saskia Middeldorp; Susanna M Zuurbier; Suzanne C Cannegieter; Jonathan M Coutinho Journal: Semin Thromb Hemost Date: 2016-06-06 Impact factor: 4.180
Authors: S Cakmak; L Derex; M Berruyer; N Nighoghossian; F Philippeau; P Adeleine; M Hermier; J C Froment; P Trouillas Journal: Neurology Date: 2003-04-08 Impact factor: 9.910
Authors: P W Kamphuisen; J C Eikenboom; H L Vos; R Pablo; A Sturk; R M Bertina; F R Rosendaal Journal: Thromb Haemost Date: 1999-05 Impact factor: 5.249
Authors: José M Ferro; Patrícia Canhão; Jan Stam; Marie-Germaine Bousser; Fernando Barinagarrementeria Journal: Stroke Date: 2004-02-19 Impact factor: 7.914
Authors: Peter B Sporns; Heather J Fullerton; Sarah Lee; Helen Kim; Warren D Lo; Mark T Mackay; Moritz Wildgruber Journal: Nat Rev Dis Primers Date: 2022-02-24 Impact factor: 52.329
Authors: Laura Martos; Julia Oto; Álvaro Fernández-Pardo; Emma Plana; María José Solmoirago; Fernando Cana; David Hervás; Santiago Bonanad; Fernando Ferrando; Francisco España; Silvia Navarro; Pilar Medina Journal: Int J Mol Sci Date: 2020-08-06 Impact factor: 5.923